The US regulator has proposed reforms to the 340B drug discount program, which provides discounts on prescription medications to certain healthcare providers. This proposal aims to increase transparency and accountability in the program. The reforms create a compliance obligation for hospitals and other healthcare providers that participate in the program. The proposed changes affect the way healthcare providers participate in the program and the way discounts are calculated.

Full News Breakdown

• The proposal suggests reforms to the 340B drug discount program, which has been a subject of controversy among healthcare providers and pharmaceutical companies.

• The program has been criticized for its lack of transparency and accountability, with some arguing that it is being abused by certain healthcare providers.

• The proposed reforms aim to increase transparency and accountability in the program by changing the way healthcare providers participate and the way discounts are calculated.

• Key provisions of the proposal include changes to the way healthcare providers participate in the program and the way discounts are calculated.

• The proposal affects the healthcare industry, particularly hospitals and other healthcare providers that participate in the program.

How Does This Affect You?

The proposed reforms to the 340B drug discount program resolve uncertainty and risk in the healthcare industry, particularly for hospitals and other healthcare providers that participate in the program. The reforms clarify the rules and requirements for participating in the program, which reduces the risk of non-compliance and associated penalties. Healthcare providers may wish to reassess their participation in the program and review their business practices.

For Lawyers & Advocates

• Healthcare providers participating in the 340B program may want to review and revise contracts and agreements related to the program, such as those with pharmaceutical companies and contract pharmacies.

• Lawyers advising healthcare providers may find it useful to take into account the proposed reforms when advising clients on compliance with the program.

• The reforms affect the way pharmaceutical companies interact with healthcare providers, and lawyers may want to consider the potential implications for distribution agreements and discount pricing structures.

• The proposed reforms raise questions about the interpretation and application of relevant laws and regulations, such as the Patient Protection and Affordable Care Act (ACA) and the Public Health Service Act (PHSA).

For Law Students

• The proposed reforms to the 340B program provide an opportunity to examine the concept of drug discount programs and the regulation of pharmaceutical prices.

• Relevant cases to read alongside this proposal include Pharmaceutical Research and Manufacturers of America v. Walsh (2003) and Astra USA v. Santa Clara County (2009), which address the regulatory framework surrounding pharmaceutical pricing and discount programs.

• The proposed reforms highlight the importance of understanding the complex interplay between healthcare providers, pharmaceutical companies, and government regulators.

• The decision provides an opportunity to analyze the reforms and their potential effects on the industry.

For Businesses

• Healthcare providers participating in the 340B program may want to review their participation and review their business practices to take into account the proposed reforms.

• Pharmaceutical companies may want to consider the potential implications of the proposed reforms for their contracts and agreements with healthcare providers.

• Companies that provide services to healthcare providers may want to adapt their services to help clients review their contracts and compliance strategies.

• Companies that manufacture or distribute pharmaceuticals may want to review their pricing and discounting practices to take into account the proposed reforms.

Key Takeaways

• The proposed reforms to the 340B program increase transparency and accountability in the program, potentially reducing the risk of non-compliance and associated penalties for healthcare providers.

• Healthcare providers participating in the program may want to review their contracts and agreements related to the program.

• The proposed reforms affect the way pharmaceutical companies interact with healthcare providers, and may require changes to contracts and agreements related to the program.

• The US Department of Health and Human Services may take further action to implement the proposed reforms, which could provide additional clarity and direction for healthcare providers and pharmaceutical companies.

• Healthcare providers may wish to review their participation in the 340B program and review their business practices before the proposed reforms are implemented.

References

1. Public Law 111–148 111th Congress An Act

2. Public Law 118–14 118th Congress An Act

3. Docket for 22A901

4. ASTRA USA, INC. v.SANTA CLARA COUNTY

5. U.S. Department of Health and Human Services (HHS) | USAGov

Source: law.com/2026/07/13/new-proposal-signals-big-changes-ahead-for-embattled-drug-discount-program/